Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGRFS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļGrifols SA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 17, 2006
āļāļĩāļāļĩāđāļAbia (Jose Ignacio)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ23833
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒDepository Receipt
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 17
āļāļĩāđāļāļĒāļđāđParque Empresarial Can Sant Joan
āđāļĄāļ·āļāļSANT CUGAT DEL VALLES
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻSpain
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ08174
āđāļāļĢāļĻāļąāļāļāđ34935710000
āđāļ§āđāļāđāļāļāđhttps://www.grifols.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGRFS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 17, 2006
āļāļĩāļāļĩāđāļAbia (Jose Ignacio)
Ms. Laura De La Cruz Galan
Ms. Laura De La Cruz Galan
Non-Member Assistant Secretary of the Board
Non-Member Assistant Secretary of the Board
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
Mr. Joerg Schuettrumpf
Chief Scientific Innovation Officer
Chief Scientific Innovation Officer
Mr. Paul S. Herendeen
Proprietary Director
Mr. Daniel Fleta Coit
Chief Industrial Services Officer
Chief Industrial Services Officer
Mr. Victor Grifols Deu
Proprietary Director
Ms. Montserrat Munoz Abellana
Ms. Montserrat Munoz Abellana
Independent Director
Mr. Inigo Sanchez-Asiain Mardones
Mr. Inigo Sanchez-Asiain Mardones
Independent Director
Ms. Susana Gonzalez Rodriguez
Ms. Susana Gonzalez Rodriguez
Independent Director
Mr. Jordi Balsells Valls
President - Plasma Procurement
President - Plasma Procurement
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Ms. Laura De La Cruz Galan
Ms. Laura De La Cruz Galan
Non-Member Assistant Secretary of the Board
Non-Member Assistant Secretary of the Board
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
Mr. Joerg Schuettrumpf
Chief Scientific Innovation Officer
Chief Scientific Innovation Officer
Mr. Paul S. Herendeen
Proprietary Director
Mr. Daniel Fleta Coit
Chief Industrial Services Officer
Chief Industrial Services Officer
Mr. Victor Grifols Deu
Proprietary Director
AdvisorShares Dorsey Wright ADR ETF
Brandes International ETF
Brandes US Small-Mid Cap Value ETF
Capital Group International Core Equity ETF
ProShares Ultra Nasdaq Biotechnology
Invesco Nasdaq Biotechnology ETF
iShares Biotechnology ETF
ActivePassive International Equity ETF
State Street SPDR S&P Kensho New Econ Comp ETF
SPDR Portfolio Developed World ex-US ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
AdvisorShares Dorsey Wright ADR ETF
āļŠāļąāļāļŠāđāļ§āļ2.19%
Brandes International ETF
āļŠāļąāļāļŠāđāļ§āļ1.85%
Brandes US Small-Mid Cap Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.85%
Capital Group International Core Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.18%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.13%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.11%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
ActivePassive International Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.08%
State Street SPDR S&P Kensho New Econ Comp ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
SPDR Portfolio Developed World ex-US ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
436.88M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
GRFS.NB Final Cash Dividend of gross USD 0.175789 paid on Aug 20, 2025 going ex on Aug 12, 2025
GRFS.NB Interim Cash Dividend of gross USD 0.456586 paid on Jun 14, 2021 going ex on Jun 03, 2021
GRFS.NB Interim Cash Dividend of gross USD 0.201439 paid on Nov 09, 2020 going ex on Oct 30, 2020